Pfizer Inc. took the diabetes industry by surprise in October when it announced it would discontinue sales of Exubera inhaled insulin, after only a little over a year on the US market, due to poor sales performance. The company also will cease further investments in a second-generation inhaled insulin device, currently in development. As a result of the decision, Pfizer will take a $2.8 billion pretax charge in the third quarter to write off product assets and inventory.
Pfizer invested more than a decade of time and money on the development of Exubera, in collaboration with Nektar Therapeutics, which pioneered the technology and manufactures the device for Pfizer....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?